Boston Scientific Corporation $BSX Shares Purchased by BTC Capital Management Inc.

BTC Capital Management Inc. grew its position in shares of Boston Scientific Corporation (NYSE:BSX) by 57.6% during the 1st quarter, Holdings Channel reports. The firm owned 84,238 shares of the medical equipment provider’s stock after purchasing an additional 30,778 shares during the period. BTC Capital Management Inc.’s holdings in Boston Scientific were worth $5,285,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Renaissance Group LLC acquired a new position in shares of Boston Scientific in the 4th quarter worth $28,064,000. Rathbones Group PLC boosted its position in shares of Boston Scientific by 20.9% in the 4th quarter. Rathbones Group PLC now owns 2,759,657 shares of the medical equipment provider’s stock valued at $263,133,000 after purchasing an additional 477,680 shares during the period. Tounjian Advisory Partners LLC purchased a new position in Boston Scientific in the 4th quarter worth about $1,477,000. Waycross Partners LLC acquired a new stake in Boston Scientific during the 4th quarter worth about $2,384,000. Finally, Kepler Cheuvreux Suisse SA acquired a new stake in Boston Scientific during the 3rd quarter worth about $26,955,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Activity

In other news, Director Cheryl Pegus purchased 1,770 shares of the stock in a transaction that occurred on Wednesday, May 20th. The stock was acquired at an average price of $56.49 per share, with a total value of $99,987.30. Following the purchase, the director owned 1,770 shares in the company, valued at $99,987.30. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Edward J. Ludwig acquired 3,580 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average price of $56.68 per share, for a total transaction of $202,914.40. Following the acquisition, the director directly owned 25,359 shares of the company’s stock, valued at $1,437,348.12. The trade was a 16.44% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders bought a total of 9,800 shares of company stock worth $554,012 in the last three months. 0.34% of the stock is owned by insiders.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Jefferies kept a Buy rating on Boston Scientific and still sees upside, even after cutting its price target to $67 from $100. Piper Sandler also maintained an Overweight rating, suggesting some analysts remain constructive on the long-term story.
• Positive Sentiment: Analyst coverage continues to frame BSX as oversold with potential upside, which may help support investor confidence if the company can avoid further setbacks.
• Neutral Sentiment: Recent market commentary noted Boston Scientific has been trading well below prior levels, with investors reassessing valuation after the sharp move lower.
• Negative Sentiment: Boston Scientific disclosed a nationwide, firm-initiated recall of Orca Single Use Air/Water and Suction Valves after reports that suction buttons could stick during gastrointestinal endoscopy procedures. The FDA classified the action as a Class II recall, which raises quality-control and regulatory concerns.
• Negative Sentiment: The recall adds to investor worries that even smaller accessory-device issues can hurt operations, increase oversight costs, and pressure sentiment around the company’s medical-device portfolio.
• Negative Sentiment: Options activity also turned more cautious, with unusual buying of put options suggesting some traders are positioning for additional downside in BSX.
• Negative Sentiment: Commentary from Jim Cramer added to the bearish tone, saying the sector is “too hard to own” right now and expressing surprise at the decline in Boston Scientific shares.

Wall Street Analysts Forecast Growth

BSX has been the topic of several analyst reports. Leerink Partners dropped their target price on shares of Boston Scientific from $87.00 to $74.00 and set an “outperform” rating on the stock in a research report on Thursday, May 28th. Wells Fargo & Company reiterated an “equal weight” rating and set a $55.00 price objective (down from $75.00) on shares of Boston Scientific in a research report on Thursday, May 28th. Argus raised shares of Boston Scientific to a “strong-buy” rating in a research note on Thursday, February 26th. Stifel Nicolaus set a $75.00 target price on Boston Scientific in a report on Wednesday, May 27th. Finally, Wall Street Zen downgraded Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $83.76.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $44.34 on Thursday. The firm has a market cap of $65.90 billion, a price-to-earnings ratio of 18.55, a P/E/G ratio of 0.87 and a beta of 0.56. Boston Scientific Corporation has a 1 year low of $44.05 and a 1 year high of $109.50. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. The business has a fifty day simple moving average of $53.67 and a 200 day simple moving average of $71.70.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. During the same quarter in the previous year, the company posted $0.75 earnings per share. The business’s quarterly revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, sell-side analysts predict that Boston Scientific Corporation will post 3.36 earnings per share for the current fiscal year.

Boston Scientific declared that its board has authorized a stock buyback plan on Monday, May 18th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock buyback plans are usually an indication that the company’s board of directors believes its shares are undervalued.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.